| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5574 | 104054-27-5 |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D058669 | Adrenergic alpha-2 Receptor Antagonists |
| MeSH PA | D000317 | Adrenergic alpha-Antagonists |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
None
| Species | Use | Relation |
|---|---|---|
| Dogs | Reverses the effects of dexmedetomidine hydrochloride | Indication |
| Dogs | Reverses the effects of medetomidine hydrochloride | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Antisedan | Orion Corp. | 1 |
| REVERTIDINE | Modern Veterinary Therapeutics LLC | 1 |
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-2A adrenergic receptor | GPCR | Ki | 8.73 | CHEMBL | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 8.65 | CHEMBL | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 8.38 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 5.71 | CHEMBL |
| ID | Source |
|---|---|
| CHEMBL353972 | ChEMBL_ID |
| C050701 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12576 | IUPHAR_LIGAND_ID |
| 104075-48-1 | SECONDARY_CAS_RN |
| DB11481 | DRUGBANK_ID |
| 019299 | NDDF |
| 019300 | NDDF |
| C0052593 | UMLSCUI |
| 6144 | INN_ID |
| 125709001 | SNOMEDCT_US |
| 763010009 | SNOMEDCT_US |
| D03002 | KEGG_DRUG |
| 71310 | PUBCHEM_CID |
| 18475 | RXNORM |
| 03N9U5JAF6 | UNII |
None